PDS Biotechnology Co. (NASDAQ:PDSB – Get Rating) – Cantor Fitzgerald lowered their FY2023 EPS estimates for shares of PDS Biotechnology in a research note issued on Tuesday, May 16th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings of ($1.62) per share for the year, down from their prior estimate of […]
U.S. and European Union exports of sensitive, so-called dual-use goods to countries in Russia's neighborhood rose sharply in 2022. So did these countries' shipments of these products to Russia, often by a similar multiple, an analysis of United Nations. | 06:20am
North American Morning Briefing: Hopes Build for -3- morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
FRP Advisory Group PLC - London-based business advisory. | May 15, 2023
PDS Biotechnology Corp. (PDSB), a clinical-stage immunotherapy company, Monday, reported a wider loss for the first quarter, particularly impacted by personnel, clinical studies, medical affairs, and manufacturing expenses.